Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545348 | 0.80 | PDK1 (0.41) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL10061686 | 0.75 | POLB (0.37) | BRD4 | |
| SCHEMBL20462066 | 0.68 | NOTUM (0.40) | BRD4 | |
| SCHEMBL13382915 | 0.68 | NPC1 (0.46) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL13383385 | 0.67 | BRD4 (0.53) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL13545353 | 0.66 | PDE7A (0.32) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL13382924 | 0.66 | GRIA1 (0.38) | — | |
| SCHEMBL10061748 | 0.65 | HTR5A (0.53) | PDK2BRD4CREBBP | |
| SCHEMBL13606863 | 0.65 | PDK1 (0.30) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL13545356 | 0.64 | ACE (0.46) | PDK1PDK2PDK3PDK4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | PDK1 195/4885PDK2 473/4885PDK3 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.